AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Jan 31, 2014

AbbVie Reports Fourth-Quarter and Full-Year 2013 Financial Results

NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

Jan 15, 2014

AbbVie Announces Initiation of Pivotal Phase 3 Study of Veliparib (ABT-888) for Patients with Early-Stage Triple-Negative Breast Cancer

NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer.  The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy. 

Jan 13, 2014

AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call

NORTH CHICAGO, Ill., Jan. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens.

Dec 20, 2013

AbbVie to Present at 32nd Annual J.P. Morgan Healthcare Conference

NORTH CHICAGO, Ill., Dec. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m. Central time.

Dec 10, 2013

AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C

NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic, genotype 1 (GT1) hepatitis C virus (HCV) infection. In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR12) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 96 percent and 97 percent, respectively. Virologic relapse or breakthrough was noted in 2 percent of patients receiving the 3D regimen plus ribavirin. In addition, the discontinuation rate due to adverse events was 1 percent.

Nov 26, 2013

AbbVie Partners with HIV Community to Launch International Awareness Campaign Focused on Women Living with HIV

NORTH CHICAGO, Ill., Nov. 26, 2013 /PRNewswire/ -- In advance of World AIDS Day on December 1, 2013, AbbVie (NYSE: ABBV) today announced the launch of See Us: Women Take a Stand on HIV, an international awareness campaign focused on helping to address the unique challenges faced by women living with HIV. The campaign is being launched in collaboration with an expert steering committee, which includes representation from women living with and affected by HIV, the medical community, the International Association of Providers in AIDS Care (IAPAC), and NAM/aidsmap, the HIV information charity.

Nov 18, 2013

AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR12) of 96 percent. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 95 percent and 98 percent, respectively. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. In addition, discontinuation rates due to adverse events were low, and of an equal percentage (0.6 percent) in both active and placebo groups.

Nov 18, 2013

AbbVie and North Chicago Public Schools Announce $350,000 Grant to Advance Math Education

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie, one of the nation's largest biopharmaceutical companies, and the North Chicago public schools announce a $350,000 grant for math education.  The grant will enable educators to strengthen and reinforce the math curriculum for students (K-8) in the district and assist in the implementation of an engaging, common core aligned curriculum designed to increase both the educator and student understanding of and proficiency in mathematics.

Nov 14, 2013

AbbVie to Present at Jefferies 2013 Healthcare Conference

NORTH CHICAGO, Ill., Nov. 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2013 Healthcare Conference on Thursday, Nov. 21, 2013. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 10:40 a.m. Greenwich Meantime (4:40 a.m. Central time).

Nov 07, 2013

AbbVie to Present at Credit Suisse 2013 Healthcare Conference

NORTH CHICAGO, Ill, Nov. 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2013 Healthcare Conference on Thursday, Nov. 14, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 9:30 a.m. Central time.